title: [Evolution of the pharmacological management of osteoarthritis: the biologics].
abstract: Proinflammatory cytokines such as IL-1 β et TNF α are implicated in osteoarthritis where they contribute to the local synovitis. Blocking IL-1 β is a promising tool in experimental animal's model of osteoarthritis (OA). So far in human clinical trials using IL-1 blockers, the results are inconclusive. The blockade of TNF α seems more appropriated for inflammatory forms of hand OA with some encouraging results. Intra-articular administration of biologics is hampered by their short resident time into the joint. Gene therapy is one of the possible way to prolong the local intra-articular delivery of biologics.
authors.affiliation: Hôpital Henri-Mondor, service de rhumatologie, 94010 Créteil, France. xavier.chevalier@hmn.aphp.fr
authors.forename: Xavier
authors.initials: X
authors.lastname: Chevalier
mesh_terms: D000818:Animals; D001688:Biological Products / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D010003:Osteoarthritis / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D001688:Biological Products; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha